Literature DB >> 16842453

Systematic review and meta-analysis: importance of CagA status for successful eradication of Helicobacter pylori infection.

T Suzuki1, K Matsuo, A Sawaki, H Ito, K Hirose, K Wakai, S Sato, T Nakamura, K Yamao, R Ueda, K Tajima.   

Abstract

BACKGROUND: Some, but not all studies have provided evidence that the CagA status of Helicobacter pylori strains is a predictive factor for the outcome of eradication therapy. AIM: To clarify the association between CagA status and eradication outcome.
METHODS: We included studies reporting the numbers of successful and failed cases in H. pylori-eradication therapy according to the CagA status. Fourteen studies (1529 patients) were included of 325 articles identified in the search. The pooled risk ratio for H. pylori-eradication failure in CagA-negative relative to CagA-positive strains and the pooled risk difference in eradication success between the two groups were used as summary statistics. Meta-regression was used for examining the source of heterogeneity.
RESULTS: The summary risk ratio for eradication failure in CagA-negative relative to CagA-positive was 2.0 (95% CI: 1.6-2.4, P < 0.001), corresponding with the summary risk difference for eradication success between the groups of 11% (95% CI: 3-19%, P = 0.011). Meta-regression analysis demonstrated that usage of polymerase chain reaction examination for CagA status and a high proportion of non-ulcer dyspepsia patients were factors for heterogeneity among studies.
CONCLUSIONS: Our meta-analysis confirmed the importance of the presence of CagA as a predictor for successful eradication of H. pylori.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16842453     DOI: 10.1111/j.1365-2036.2006.02994.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  18 in total

1.  First-line eradication of Helicobacter pylori: are the standard triple therapies obsolete? A different perspective.

Authors:  György-Miklós Buzás
Journal:  World J Gastroenterol       Date:  2010-08-21       Impact factor: 5.742

2.  Association of helicobacter pylori dupA with the failure of primary eradication.

Authors:  Seiji Shiota; Lam Tung Nguyen; Kazunari Murakami; Akiko Kuroda; Kazuhiro Mizukami; Tadayoshi Okimoto; Masaaki Kodama; Toshio Fujioka; Yoshio Yamaoka
Journal:  J Clin Gastroenterol       Date:  2012-04       Impact factor: 3.062

3.  Clinical significance of Helicobacter pylori cagA and iceA genotype status.

Authors:  Nasser Amjad; Hussain Ali Osman; Najibah Abdul Razak; Junaini Kassian; Jeffri Din; Nasuruddin bin Abdullah
Journal:  World J Gastroenterol       Date:  2010-09-21       Impact factor: 5.742

Review 4.  The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America.

Authors:  M Constanza Camargo; Apolinaria García; Arnoldo Riquelme; William Otero; Claudia A Camargo; Tomas Hernandez-García; Roberto Candia; Michael G Bruce; Charles S Rabkin
Journal:  Am J Gastroenterol       Date:  2014-03-04       Impact factor: 10.864

Review 5.  Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy.

Authors:  Mitsushige Sugimoto; Yoshio Yamaoka
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2009-02-14       Impact factor: 4.291

Review 6.  Helicobacter and salmonella persistent infection strategies.

Authors:  Denise M Monack
Journal:  Cold Spring Harb Perspect Med       Date:  2013-12-01       Impact factor: 6.915

7.  Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance.

Authors:  Ju Yup Lee; Nayoung Kim; Min Soo Kim; Yoon Jin Choi; Jung Won Lee; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Dong Ho Lee; Hyun Chae Jung
Journal:  Dig Dis Sci       Date:  2014-03-06       Impact factor: 3.199

Review 8.  Choosing optimal first-line Helicobacter pylori therapy: a view from a region with high rates of antibiotic resistance.

Authors:  Alexander A Nijevitch; Bulat Idrisov; Elsa N Akhmadeeva; David Y Graham
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 9.  Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention.

Authors:  Iris Lansdorp-Vogelaar; Linda Sharp
Journal:  Best Pract Res Clin Gastroenterol       Date:  2013-09-27       Impact factor: 3.043

10.  Effect of smoking on failure of H. pylori therapy and gastric histology in a high gastric cancer risk area of Colombia.

Authors:  M Constanza Camargo; M Blanca Piazuelo; Robertino M Mera; Elizabeth T H Fontham; Alberto G Delgado; M Clara Yepez; Cristina Ceron; Luis E Bravo; Juan C Bravo; Pelayo Correa
Journal:  Acta Gastroenterol Latinoam       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.